DNA to Protein: The Central Dogma

The Central Dogma: DNA → RNA → Protein

In 1958, Francis Crick articulated what he called the "Central Dogma of Molecular Biology" — the principle that genetic information flows from DNA to RNA to protein, and not in reverse. This single concept underpins modern genetics, medicine, and biotechnology. Understanding it gives you the framework to understand cancer, genetic disorders, evolution, antibiotic resistance, and virtually every molecular therapy in modern medicine.

DNA Structure: The Blueprint

DNA (deoxyribonucleic acid) is a double-stranded helical molecule consisting of nucleotide monomers. Each nucleotide contains a deoxyribose sugar, a phosphate group, and one of four nitrogenous bases: adenine (A), thymine (T), guanine (G), or cytosine (C). The two strands are held together by hydrogen bonds between complementary bases: A pairs with T (2 hydrogen bonds), and G pairs with C (3 hydrogen bonds).

In humans, approximately 3.2 billion base pairs are organized into 46 chromosomes (23 pairs) within the nucleus of every somatic cell. This entire sequence — the genome — encodes approximately 20,000–25,000 protein-coding genes, which account for only about 1.5% of total DNA. The remaining DNA includes regulatory sequences, structural elements, transposable elements, and regions whose functions are still being elucidated.

Step 1: DNA Replication — Copying the Blueprint

Before a cell divides, it must duplicate its entire genome so each daughter cell receives a complete copy. This process — DNA replication — occurs during the S (synthesis) phase of the cell cycle and is semi-conservative: each resulting double helix contains one original (parental) strand and one newly synthesized strand.

The key steps:

1. Initiation: Replication begins at specific sequences called origins of replication. Humans have thousands of origins, allowing simultaneous replication of the entire genome. The enzyme helicase unwinds and separates the double helix, creating two template strands and a replication fork.
2. Priming: DNA polymerase cannot begin synthesis without a free 3'-OH group. Primase synthesizes short RNA primers complementary to the template, providing the starting point.
3. Elongation: DNA polymerase III adds complementary deoxyribonucleotides (dNTPs) to the 3' end of the growing strand, always working 5'→3'. The leading strand is synthesized continuously; the lagging strand is synthesized in short segments called Okazaki fragments.
4. Completion: RNA primers are removed and replaced with DNA. DNA ligase seals the nicks between Okazaki fragments, producing a continuous strand. Proofreading by DNA polymerase reduces the error rate to approximately 1 mistake per 10 billion base pairs.

Step 2: Transcription — DNA to mRNA

Transcription is the process by which the information in a specific gene (segment of DNA) is copied into messenger RNA (mRNA). It occurs in the nucleus and is performed by RNA polymerase.

1. Initiation: Transcription factors bind to the promoter region (usually containing a TATA box ~25–30 bp upstream of the start site) and recruit RNA polymerase II to the gene. RNA polymerase unwinds the DNA double helix, exposing the template strand.
2. Elongation: RNA polymerase reads the template strand 3'→5' and synthesizes a complementary RNA strand 5'→3'. RNA uses uracil (U) instead of thymine (T), so the base-pairing rule becomes: A pairs with U, T pairs with A, G pairs with C.
3. Termination: Transcription continues until a termination sequence is reached. The RNA polymerase and the newly made pre-mRNA transcript dissociate from the DNA template.

mRNA Processing (in eukaryotes): The initial transcript (pre-mRNA) undergoes extensive processing before leaving the nucleus:

• 5' capping: A modified guanosine cap is added to the 5' end — protects mRNA from degradation and aids ribosome recognition.
• Polyadenylation: A poly-A tail (100–250 adenine residues) is added to the 3' end — increases stability and aids nuclear export.
• Splicing: Introns (non-coding intervening sequences) are removed by the spliceosome, and exons (expressed sequences) are joined together. Alternative splicing allows one gene to produce multiple different proteins — dramatically expanding proteome diversity from a limited genome.

Step 3: Translation — mRNA to Protein

Translation is the decoding of the mRNA sequence into a sequence of amino acids — a polypeptide chain that folds into a functional protein. It occurs at ribosomes in the cytoplasm (or on the rough endoplasmic reticulum for secreted/membrane proteins).

The genetic code is triplet — each 3-base codon in the mRNA specifies one amino acid. There are 64 possible codons encoding 20 amino acids plus stop signals (the code is degenerate — most amino acids are encoded by multiple codons). The code is essentially universal across all life on Earth.

1. Initiation: The small ribosomal subunit (40S in eukaryotes) scans the mRNA from the 5' cap until it finds the start codon AUG. The initiator tRNA (carrying methionine, anticodon UAC) base-pairs with AUG. The large ribosomal subunit (60S) joins, forming the complete ribosome (80S) with three tRNA sites: E (exit), P (peptidyl), and A (aminoacyl).
2. Elongation: A charged tRNA (carrying the next amino acid) enters the A site. If its anticodon is complementary to the codon in the A site, a peptide bond forms between the growing polypeptide (in the P site) and the new amino acid (in the A site) — catalyzed by peptidyl transferase (an RNA enzyme, a ribozyme). The ribosome translocates one codon in the 3' direction: the tRNA in the A site moves to P, the tRNA in P moves to E and exits. The next tRNA enters the A site. This cycle repeats up to 20 times per second.
3. Termination: When a stop codon (UAA, UAG, or UGA) enters the A site, no tRNA can base-pair with it. Instead, release factors bind, hydrolyze the polypeptide from the last tRNA, and the ribosome disassembles.

The newly synthesized polypeptide chain folds spontaneously (often assisted by molecular chaperones) into its three-dimensional structure, which determines its function. Post-translational modifications (phosphorylation, glycosylation, ubiquitination, etc.) further regulate protein activity, location, and lifespan.

Clinical and Biotechnological Relevance

• Cancer: Mutations in DNA (proto-oncogenes, tumor suppressor genes) alter protein function, disrupting the cell cycle. Understanding the central dogma allows us to design targeted therapies against specific mutant proteins (e.g., imatinib targeting BCR-ABL in CML).
• mRNA Vaccines (COVID-19): Synthetic mRNA encoding the SARS-CoV-2 spike protein is delivered into cells, which then translate it into spike protein, inducing an immune response — without any DNA integration or risk of infection. This is the central dogma in action as medicine.
• CRISPR-Cas9: A bacterial immune system repurposed to edit DNA directly — cutting, replacing, or silencing specific gene sequences. The most powerful tool in genetic medicine.
• Antibiotic mechanisms: Many antibiotics target bacterial ribosomes (translation) or DNA replication enzymes without harming human counterparts — exploiting the differences between prokaryotic and eukaryotic molecular machinery.